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Background: Toxoplasma gondii is an obligate
intracellular protozoan infecting up to one-third of the
world’s population, constituting a life threat if
transmitted from mother to child during pregnancy. In
Portugal, there is a lack of knowledge of the current
epidemiological situation, as the unique toxoplasmosis
National Serological Survey was performed in 1979/
1980.
Methods: We studied the seroprevalence trends in the
Portuguese general population over the past 3
decades, by assessing chronological spread cross-
sectional studies, with special focus on women of
childbearing age, by age group, region and gender.
Results: The T. gondii overall seroprevalence
decreased from 47% in 1979/1980 to 22% (95% CI
20% to 24%) in 2013. Generally, we observed that the
prevalence of T. gondii IgG increased significantly with
age and it decreased over time, both in the general
population and in the childbearing women (18%
prevalence in 2013).
Conclusions: The scenario observed for the latter
indicates that more than 80% of childbearing women
are susceptible to primary infection yielding a risk of
congenital toxoplasmosis and respective sequelae.
Since there is no vaccine to prevent human
toxoplasmosis, the improvement of primary prevention
constitutes a major tool to avoid infection in such
susceptible groups.
INTRODUCTION
Toxoplasma gondii is an obligate intracellular
protozoan parasite belonging to the phylum
apicomplexa that infects most mammals
worldwide. It undergoes a sexual cycle in the
intestinal epithelium of the deﬁnitive host,
members of the cat family, where it turns into
oocysts, which are subsequently shed in the
environment. It also undergoes an asexual
cycle in intermediate hosts, such as birds,
rodents and other mammals including
human beings.1 Oocysts are extremely stable
in the environment, and are transmitted to
other hosts through inadvertent ingestion.
Humans acquire T. gondii through ingestion
of tissue cysts in the undercooked meat of
intermediate hosts, mainly pork and lamb, or
by the ingestion of water or food contami-
nated by faeces containing oocysts from
the deﬁnitive host,2 and rarely through
transplantation of an infected organ.3 While
toxoplasmosis is often benign in immuno-
competent individuals (revealing no symp-
toms or may experience swollen lymph
nodes), it induces major complications in
immunocompromised individuals and during
pregnancy, constituting a life-threatening
disease. Congenital toxoplasmosis (transmis-
sion to the fetus when a pregnant woman
acquires T. gondii infection for the ﬁrst time
during pregnancy) can result in abortion or
lead to severe malformation of the fetus or to
visual or neurological injuries in the
newborn, such as hydrocephalus, cerebral cal-
ciﬁcation and/or chorioretinitis. Such
patients may require prolonged, sometimes
Strengths and limitations of this study
▪ The results of the present study fill an important
gap in the Toxoplasma gondii seroprevalence in
the Portuguese population as no data were avail-
able for the past 30 years.
▪ This study indicates that more than 80% of the
Portuguese childbearing women are susceptible
to primary infection, yielding a risk of congenital
toxoplasmosis and respective sequelae.
▪ Different serological methods were used in the
three cross-sectional studies, with possible sen-
sitivity and/or specificity dissimilarities, which
could not be overcome due to the chronological
distance between them.
▪ The study of risk factors could not be performed
due to the lack of more complete personal,
socioeconomic and demographic information.
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lifelong, therapy. Also, recent studies suggest that subtle
behavioural or personality changes may occur in
T. gondii-infected humans,4 and toxoplasmosis has
recently been associated with neurological disorders, par-
ticularly schizophrenia,5 and bipolar disorder.6 However,
evidence for causal relationships remains limited.7
T. gondii has a wide spectrum of prevalence across the
globe and infects up to one-third of the world’s popula-
tion.8 Cultural habits in regard to cooking food are most
likely the major cause of differences in the frequency of
infection with T. gondii in many areas of the world,
ranging from <10% to almost 100%.8–11 Consequently,
there are large differences in the incidence of congeni-
tal infection that may vary from 1:1000 live births in
France, to 1:10 000 in countries with a lower seropreva-
lence, and in the USA, it has been estimated that ∼3500
infants are born each year with congenital toxoplasmo-
sis.12 According to a recent review,13 the global status of
T. gondii seroprevalence in pregnant women or in repro-
ductive ages ranges from above 60% in countries such as
Brazil, Gabon, Indonesia, Germany and Iran, to <10% in
the UK and Korea. The surveillance schemes of toxo-
plasmosis are very heterogeneous in European coun-
tries, which hinders the burden of congenital
toxoplasmosis estimates comparison.14
The ﬁrst National Serological Survey was conducted in
continental Portugal between 1979 and 1980 and showed
T. gondii overall seroprevalence of 47%.15 Since then, no
National Serological Surveys enrolling T. gondii antibodies
were performed, but only small-scale studies.16–18 Thus,
Portuguese health national authorities consider that
there is a lack of knowledge of the current epidemio-
logical situation of toxoplasmosis in Portugal, and the
2011 guidelines of the General Directorate of Health for
toxoplasmosis screening establish the surveillance of
low-risk pregnancy based on three monthly retesting of
susceptible women.19 Of note, congenital toxoplasmosis
is a mandatory notiﬁable disease in Portugal,20 and its
diagnosis should be performed in our laboratory at the
National Reference Laboratory of Parasitic and Fungal
Infections of the Portuguese National Institute of Health.
In this regard, considering our data, there are about
three cases of congenital toxoplasmosis per year in
Portugal (data not published).
Considering that the unique overall population study
performed in Portugal dates back to 35 years ago, the
aim of this study was to describe the seroprevalence
trends in the Portuguese general population (with
special focus on women of childbearing age) over the
past three decades (1979–1980 to 2013), by age group,
region and gender.
METHODS
Study design and sampling
In order to fulﬁl the deﬁned objectives, three cross-
sectional seroprevalence studies (1979/1980, 2001/2002
and 2013) were used. All of them were based on
opportunistic sampling. Nevertheless, few biases are asso-
ciated with this strategy in our study, as sera belonged to
individuals seeking diverse blood analysis rather than
speciﬁc T. gondii evaluation, which also reﬂects the vast
majority of the general population. Furthermore, the
same methodology was applied to all three surveys,
ensuring their internal validity by increasing their com-
parability. The starting point was the T. gondii serological
data released on behalf of the First Portuguese National
Serological Survey in 1979/1980. This sample enrolled
1675 individuals of both genders, which were homoge-
neously distributed by the following stage groups:
8 months–5 years, 6–15, 16–30, 31–45 and ≥46 years.
Each age group included individuals from each of the
18 districts of Portugal (Portuguese islands were not
included) that were representative of the population of
each district.15 Then, in this study, we processed two dis-
tinct samples. The ﬁrst one was composed of sera
belonging to the Second Portuguese National
Serological Survey 2001–2002 that aimed to estimate the
prevalence of antibodies to vaccine-preventable diseases,
and for this reason the determination of antibodies for
toxoplasmosis was not performed at that time. This
sample enrolled 3525 individuals of both genders, and
covered all age groups. Similar to the ﬁrst serological
survey, each age group included a number of individuals
representative of the population of each of the 18 dis-
tricts. For the participation of individuals, a document
was prepared with the objectives and beneﬁts of the
study and informed consent was obtained either from
the participants themselves or from their legal represen-
tatives.21 From these sera, we used a subsample of 1657
sera, which was established to detect the difference in
antibodies prevalence between the 1979/1980 and
2001/2002 Portuguese National Serological Surveys of at
least 5%, with a power of 80% and a signiﬁcance level of
5%. This subsample comprehended individuals of both
genders, homogeneously distributed in ﬁve age groups:
8 months–5 years, 6–15, 16–30, 31–45 and ≥46 years.
Each age group included individuals from each of the
18 districts (as in previous surveys, proportion within dis-
tricts was ensured). It served as baseline for the estab-
lishment of the sample size of the 2013 T. gondii
serological survey, which was composed of 1440 indivi-
duals of both genders, homogeneously distributed in
the same ﬁve age groups as the previous survey. In each
age group, for both surveys, individuals were distributed
by 18 districts of Portugal (Portuguese islands were not
included) proportionally to the resident population. For
the 2013 survey, individuals were selected (to fulﬁl the
above cited requisites of age, gender and geography)
from the attendees of the private clinical laboratory of
Dr Joaquim Chaves during the period of January to
December 2013. This is the largest Portuguese labora-
tory comprehending more than 40 sampling collection
units dispersed throughout the whole country.
No informed consent was obtained from each partici-
pant as, besides the information regarding gender and
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age, no further information was available to the labora-
tory. This procedure is in agreement with the
Portuguese law No. 12/2005.22
Serological analyses
Sera regarding the 2001/2002 seroprevalence study were
analysed for the presence of T. gondii-speciﬁc antibodies
in 2012, whereas the analysis for the 2013 survey was per-
formed in 2013, both at the National Reference
Laboratory of Parasitic and Fungal Infections of the
Portuguese National Institute of Health.
T. gondii IgG-speciﬁc antibodies were detected by
using the automated methodology enzyme linked ﬂuor-
escent assay—sensibility 99.65% (interval conﬁdence
(CI) 94.55% to 97.39%), speciﬁcity 99.92% (CI 99.58%
to 100%) and cut-off 4≤titre<8 IU/mL, with the VIDAS
TOXO IgGII commercial reagents (bioMérieux SA,
Marcy-l’Étoile, France) according to the manufacturer’s
instructions. For the resolution of equivocal samples (ie,
4≤titre<8 IU/mL), we retested them using a manual
methodology of the direct agglutination test—sensibility
96.22% (CI 94.55% to 97.39%), speciﬁcity 98.80% (CI
96.46% to 99.60%) and cut-off 4 IU/mL, by using the
TOXO—Screen DA commercial reagents (bioMérieux
SA, Marcy-l’Étoile, France), according to the manufac-
turer’s instructions. Most of the epidemiological surveys
are based on the IgG titre because IgG antibody positive
titres can be detected 2–3 weeks after infection, reaching
a maximum titre within 2 months. It then declines to a
baseline level that persists throughout the remainder of
one’s life. These methodologies were not available at the
time the ﬁrst National Epidemiological Survey was per-
formed (1979/1980), which used an in house indirect
immunoﬂuorescence method.15
Statistical analysis
Statistical analysis consisted of the estimation of the sero-
prevalences among the categories of the variables sex,
age groups and region. Differences between the esti-
mated seroprevalences were analysed using the χ2 test,
considering the signiﬁcance level of 5%. The stats
package of R software (V.3.0.3) was used (R
Development Core Team. R: A language and environ-
ment for statistical computing. Vienna, Austria: R
Foundation for Statistical Computing, 2013. ISBN
3–900051–07–0, URL. http://www.R-project.org).
RESULTS
In the 2013 serological survey (n=1440), we observed an
overall prevalence of T. gondii antibodies of 22% (95%
CI 20% to 24%), whereas in the 2001/2002 survey
(n=1657) the overall prevalence of T. gondii antibodies
was 36% (95% CI 34% to 39%; ﬁgure 1A). The sero-
prevalence in the Portuguese population decreased by
11% (95% CI 7% to 14%) between 1979/198014 and
2001/2002, 14% (95% CI 11% to 17%) between 2001/
2002 and 2013, and 25% (95% CI 22% to 28%) between
1979/1980 and 2013. The signiﬁcant decreasing trend
during this 34-year period is illustrated in ﬁgure 1B.
Since there were no statistically signiﬁcant differences
between the 18 districts (data not shown), we grouped
them into four regions: north, centre, Lisbon area and
south. In the 2013 survey, the seroprevalences ranged
from 13% (CI 95% 10% to –17%) in the north of
Portugal to 33% (CI 95% 29% to 37%) in the south
region (table 1).
This ﬁnding is in opposition to the ones observed for
the serological surveys of 1979–1980 and 2001/02,
where the seroprevalence was higher in the north,
centre and Lisbon area. In particular, the north region
presented the highest levels in the ﬁrst two surveys but
the lowest in the last survey, in opposition to the south.
In general, a decreasing trend was observed for the
prevalence of T. gondii antibodies over the studied years
in the four regions, with the exception of the south
region that showed an increase of 8% (95% CI 2% to
19%) between 2001/2002 and 2013 (tables 1 and 2). In
particular, the decrease observed for the north region
between these two surveys was statistically signiﬁcant
(table 2).
Regarding the association between seroprevalence and
age, we observed that the prevalence of speciﬁc T. gondii
IgG increased signiﬁcantly with this variable for each
age group (eg, for the 2013 survey, χ2 test for trend in
proportions gives a p value <0.001) and it generally
decreased over time (ﬁgure 2). The only exception
occurred for the age group ≥46 that revealed an
increase from the 1979/1980 to the 2001/2002 survey.
Considering solely the last two surveys (no data are avail-
able for the 1979/1980 survey, except for females
between 15 and 45 years of age), the prevalence of spe-
ciﬁc T. gondii IgG decreased signiﬁcantly for all age
groups (except for 8 months–5 years; table 2).
Figure 1 (A) shows the evolution of Toxoplasma gondii
seroprevalence in Portugal over the past three decades; (B)
shows the sample sizes for the three National Serological
Surveys, the precise estimated seroprevalences and
respective 95% confidence interval (CI).
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Concerning the seroprevalence distribution by gender,
we observed no signiﬁcant differences, either for the
2001/2002 or the 2013 survey. Both genders showed a
signiﬁcant decrease in prevalence between these two
surveys (table 3).
DISCUSSION
In this study, we aimed to perform a cross-sectional
T. gondii seroprevalence study in the Portuguese popula-
tion. We acknowledge the following limitations in this
serological study, namely: (1) the lack of more complete
personal and socioeconomic and demographic informa-
tion, hampering an evaluation involving risk factors; (2)
the probable lower sensitivity and/or speciﬁcity of the
serological tests used in the ﬁrst national survey when
compared with the ones used in the latest surveys; (3)
the use of different serological methods (1979/1980 vs
the two most recent surveys); and (4) the use of both
fresh (1979/1980 and 2013 surveys) and frozen (2001/
2002) sera. We believe that some of these limitations
could impact some false-negative and/or false-positive
results and quantitative data (ie, the determination of
serological titres), but less signiﬁcantly impacted the
determination of the immune status of the enrolled
people, which was beyond the scope of this study. Also,
sensitivity and speciﬁcity of the conventional methods
most likely changed little over the years, as demon-
strated, for instance, by the maintenance of the gold
standard (Sabin-Feldman dye test) over the past
60 years. Finally, interassay variability is very unlikely to
explain the large changes in seroprevalence observed
from 1979/1980 to the 2013 survey.
The 2013 serological survey established an overall
prevalence of T. gondii-speciﬁc IgG of 22%. This value
indicates a prevalence that is similar to what has been
described for other Mediterranean countries, such as
Spain, Italy and Greece,13 23–27 which could be asso-
ciated with the similarity between these countries in
terms of: (1) climate: seroprevalence may depend on
the appropriate conditions for sporulation and oocysts
survival in the environment, as oocysts maturation and
transmission to a new host is faster at mild and wet cli-
mates,9 which are not characteristic of these countries;
(2) cat contact: cats are one of the major sources of
infection, as they shed a large amount of oocysts via
faeces, indoors and outdoors, even after ingestion of a
single bradyzoite or one tissue cyst.3 28 More, sporulated
oocysts can survive for years in water, gardens, beach
sands and farms, which constitute environmental fea-
tures that are typical of these countries, enabling similar
means of transmission due to the contact with the abun-
dant stray and domestic cats in these environments,3 28
and (3) diet: The ingestion of raw, undercooked or
cured meats is the primary risk factor in Europe for
acquiring toxoplasmosis,1 and these countries present
the same nutritional behaviour and eating habits,
namely the traditional consumption of cured meats and
raw vegetables. Although the frequent cat contact and
Table 1 Trends of Toxoplasma gondii seroprevalence in Portugal by region calculated with an interval confidence of 95%
1979/1980 2001/2002 2013
N Seroprevalence (%) n Seroprevalence (%) n Seroprevalence (%)
North 405 51% (46% to 56%) 426 45% (41% to 50%) 464 13% (10% to 17%)
Centre 590 47% (43% to 51%) 426 38% (33% to 42%) 344 29% (25% to 34%)
Lisbon 302 47% (41% to 52%) 630 33% (29% to 37%) 504 23% (20% to 27%)
South 378 43% (38% to 48%) 171 25% (19% to 32%) 128 33% (25% to 41%)
Table 2 Multivariate analysis adjusted for gender, age
group and region
Prevalence ratios from 2002 to 2013
North 0.37 (0.28 to 0.50)
Centre 0.93 (0.72 to 1.20)
Lisbon 0.84 (0.67 to 1.06)
South 1.27 (0.82 to 1.95)
8 months–5 years 0.60 (0.13 to 2.80)
6–15 years 0.21 (0.07 to 0.64)
16–30 years 0.52 (0.35 to 0.76)
31–45 years 0.70 (0.52 to 0.94)
≥46 years 0.83 (0.70 to 0.99)
The values represent the prevalence ratios between the 2013 and
the 2001/2002 serological surveys. Data are not available for the
1979/1980 survey.
Figure 2 Comparison of Toxoplasma gondii seroprevalence
trends, according to the data from three National Serological
Surveys, by age groups.
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typical diet would support higher seroprevalences than
those observed, other factors, such as the climate and
population education (discussed below), most likely
balance this trend.
We observed a huge decrease in the T. gondii sero-
prevalence in Portugal, from 1979/1980 to the 2013
survey, as the ﬁrst survey revealed a 47% rate,15 which
was low compared with the values reported in France,
but sharply high when compared with north European
countries. Curiously, the 2013 prevalence (22%) remains
low compared with France but is now sharply lower com-
pared with some countries from the north of Europe
such as Germany, Poland, Belgium, the Netherlands and
Switzerland.13 We speculate that a possible explanation
for those striking differences may rely on cultural habits
in regard to eating and cooking practices. The sharp
decreasing trend of T. gondii seroprevalence observed in
Portugal during the past 34 years has been also reported
in many studies performed in several developed coun-
tries.29 Since the consumption of raw or undercooked
meat is considered to be the major source of T. gondii
infection, we believe that this decreasing trend may be
associated with: (1) the practice of freezing meat; (2)
the changes in nutritional habits that took place in
Portugal and Europe during the past years related to the
wide access to fast foods and pre-prepared meals, includ-
ing frozen meat meals and the decreasing number of
home-prepared meals;29 (3) the introduction of inten-
sive farming techniques involving the separation of cats
from livestock, coupled with the reduction of breeding
cattle in backyards;1–29 (4) the release of legislation for
toxoplasmosis, concerning sanitary inspection in the
slaughterhouses; and (5) the improvements in health
education and information by health professionals, as
the lack of awareness of disease sources of transmission
is a crucial factor in the risk of infection.
Regarding the distribution of T. gondii seroprevalence
by geographic region, we observed an intriguing phe-
nomenon as, contradicting the continuous decrease
detected in the north, centre and Lisbon area, there was
an 8% increase (table 1) of the seroprevalence in the
south, from 2001–2002 to the 2013 survey. Also, in the
2013 survey, this region was the one with the highest
T. gondii seroprevalence (33%), which was signiﬁcantly
higher (about 2.5-fold) than the region showing the
lowest values (north—13%). The variation in the geoser-
oprevalence of this parasite may be due to the local
rainy conditions and altitude.30 Nevertheless, this would
explain the lower values observed for the south region
in the ﬁrst two surveys when compared with the other
regions, but contradicts the scenario observed in the
2013 survey, as the south of Portugal presents a promin-
ent lower altitude and is clearly drier and warmer than
the remaining regions.
In most human populations, the T. gondii seropreva-
lence increases with age, indicating that infection is
acquired throughout life.1 Our study was no exception
and showed a higher seroprevalence in older age groups
(for all geographical regions), most likely due to their
longer exposure to the risk factors.
Concerning childbearing women, we observed a signiﬁ-
cant decreasing trend in the T. gondii seroprevalence over
time (table 4). This observation is corroborated by other
studies, which show that the prevalence of T. gondii infec-
tion in women of childbearing ages has decreased over
the past 30 years,31 and consequently, more women are
now susceptible to the infection. Besides the factors stated
above that most likely justify the seroprevalence decrease
in the general population, the major factor associated with
the decline observed for this target group most likely relies
on the promotion of educational programmes yielding an
improvement of the primary prevention. The currently
observed seroprevalence of 18% indicates that about 80%
of Portuguese women are not immune against the
T. gondii infection. Thus, the majority of potential preg-
nant women are susceptible to primary infection and the
Table 3 Toxoplasma gondii seroprevalence by gender
and year of analysis calculated with an interval confidence
of 95%
Male Female
N Prevalence (%) n Prevalence (%)
2002 641 35% (31% to 39%) 1016 38% (35% to 41%)
2013 638 22% (19% to 25%) 802 23% (20% to 26%)
Among the female population, we considered childbearing women
aged 15–45 years, and observed a significant decreasing trend in
the seroprevalence in this group: 53% (95% CI 48% to 59%) in
1979–1980, 35% (95% CI 32% to 38%) in 2001/2002 and 18%
(95% CI 14% to 22%) in 2013. We also subdivided this population
into five groups: 15–20, 21–26, 27–32, 33–38 and 39–45 years
and observed that, like in the general population, there was a
significant increase of T. gondii seroprevalence with age (except
for a unique age group within the 1979–1980 survey), and a
significant decreasing trend over time (table 4).
Table 4 Toxoplasma gondii seroprevalence in childbearing women by age group calculated with an interval confidence of
95%
1979 2002 2013
"15–20″ 51% (41% to 60%) 19% (14% to 25%) 4% (2% to 10%)
"21–26″ 56% (44% to 67%) 23% (18% to 30%) 10% (4% to 19%)
"27–32″ 46% (35% to 58%) 34% (28% to 41%) 17% (10% to 28%)
"33–38″ 60% (45% to 72%) 48% (40% to 56%) 32% (20% to 49%)
"39–45″ 60% (47% to 72%) 62% (53% to 69%) 50% (37% to 63%)
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risk of congenital toxoplasmosis is high, a scenario that
mirrors the one observed for several cities in Spain.32 The
low prevalence observed among women of childbearing
age should not be neglected. In fact, a recent study from
the WHO,33 which estimated the global burden of con-
genital toxoplasmosis by using a previously described pre-
diction model,34 alerts that the global burden of the
disease is considerably higher than that suggested by the
congenital toxoplasmosis data. The incidence of infection
is dependent on the general seroprevalence, determining
the population susceptibility and the frequency of risk
factors for toxoplasmosis acquisition. Therefore, sero-
prevalence should be considered the indicator to establish
screening policies. Regarding this issue, several countries
have no surveillance of the infection, whereas others focus
solely on severe cases and few have surveillance targeted at
congenital toxoplasmosis.35 In Portugal, there is a surveil-
lance system, which includes both the screening of preg-
nant women with follow-up during pregnancy of those
who are not immune, in order to detect seroconversion,
and the mandatory laboratory notiﬁcation of congenital
toxoplasmosis cases detected during this process.19
This study reinforces that prenatal screening for toxo-
plasmosis is necessary due to the high rate of seronega-
tive women exposed to infection and the probability of a
high number of primary infections in the childbearing
period. Targeted information should be crucially pro-
vided to childbearing and pregnant women by the
health professionals regarding consumption of
uncooked or cured meat, raw vegetables, contaminated
drinking water and contact with cats. With one excep-
tion (Toxovax for sheep), there is no approved vaccine
to prevent human or animal toxoplasmosis; therefore,
primary prevention is the major tool to prevent the
infection in the general population, mainly in high-risk
individuals, such as immunocompromised, pregnant
and childbearing women. Besides these primary pre-
vention measures, there are several actions that will
determine the prevention and control of T. gondii infec-
tion, including the governmental inspection of slaugh-
terhouses and food production industries, the
improvement of hygienic standards of abattoirs, the pro-
motion of public educational schemes and the establish-
ment of serological screening programmes.
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